← Leaderboards
Grace A McComsey
Case Western Reserve University
$52,271,489
Attributed
$56,305,333
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$56,305,333 · 17
By mechanism
UM1$24,022,255 · 1
R01$15,427,384 · 6
UL1$11,907,099 · 1
R21$1,642,110 · 4
R56$1,579,962 · 2
T32$991,142 · 1
Top collaborators
- Allison Ross Eckard5 shared
- Corrilynn Olesky Hileman5 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Aaron Weinberg$13,644,444
- Bryan K Yamamoto$12,329,126
- Corrilynn Olesky Hileman$3,071,771
- Lance T. Vernon$1,616,494
- Fengchun Ye$963,725
Others in their field
Top investigators on “Antiretroviral Therapy”
- James Dennis Neaton · Northwestern University$279,044,427
- Lawrence Corey · Fred Hutchinson Cancer Center$278,220,635
- Constance Ann Benson · University Of California, San Diego$241,336,455
- Carol Nesel · Westat$188,148,170
- Judith S. Currier · University Of California Los Angeles$182,467,520
- Barbara Driver · Westat, Inc.$170,789,549
Research focus
Antiretroviral TherapyLinkHiv TherapyClinical TrialsInflammationGeneral PopulationCardiovascular DiseasesAffectImmune ActivationInsulin ResistanceMetabolicInflammatoryResearch PersonnelCardiovascular SystemOxidative StressPharmaceutical PreparationsCardiovascular Disorder RiskFunctional DisorderLeadCardiovascular Risk FactorFundingDiabetes MellitusHiv-1Inflammatory Marker
Grant awards (57)
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages for Everyone's Health (CLE Health)$7,902,972
UM1 · FY2025 · TR · contact PI
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)$8,041,152
UM1 · FY2024 · TR · contact PI
Clinical and Translational Science Collaborative of Northern Ohio, Catalyzing Linkages to Equity in Health (CLE Health)$8,078,131
UM1 · FY2023 · TR · contact PI
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy$748,650
R01 · FY2023 · DK · contact PI
Clinical and Translational Science Collaborative of Cleveland$5,973,390
UL1 · FY2022 · TR · contact PI
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy$760,561
R01 · FY2022 · DK · contact PI
Clinical and Translational Science Collaborative of Cleveland$5,933,709
UL1 · FY2021 · TR · contact PI
The impact of intravenous heroin use on immune activation in treated HIV$857,236
R01 · FY2021 · DA · contact PI
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy$766,113
R01 · FY2021 · DK · contact PI
Role of Zinc in HIV inflammation$242,810
R33 · FY2021 · AT · contact PI
The impact of intravenous heroin use on immune activation in treated HIV$856,800
R01 · FY2020 · DA · contact PI
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy$769,710
R01 · FY2020 · DK · contact PI
Role of Zinc in HIV inflammation$242,810
R33 · FY2020 · AT · contact PI
The impact of intravenous heroin use on immune activation in treated HIV$855,636
R01 · FY2019 · DA · contact PI
Effects of GLP-l receptor agonists on cardiometabolic alterations in HIV-associated lipohypertrophy$788,897
R01 · FY2019 · DK · contact PI
Role of Zinc in HIV inflammation$241,443
R33 · FY2019 · AT · contact PI
Changes in gut integrity markers after HIV therapy and metabolic complications$166,475
R21 · FY2019 · DK · contact PI
The impact of intravenous heroin use on immune activation in treated HIV$857,694
R01 · FY2018 · DA · contact PI
Changes in gut integrity markers after HIV therapy and metabolic complications$286,474
R21 · FY2018 · DK · contact PI
The impact of intravenous heroin use on immune activation in treated HIV$806,391
R01 · FY2017 · DA · contact PI
Role of Zinc in HIV inflammation$214,848
R21 · FY2017 · AT · contact PI
Role of Zinc in HIV inflammation$226,110
R21 · FY2016 · AT · contact PI
Vitamin D, drug metabolism, and cardiovascular complications in pediatric HIV$323,245
R01 · FY2015 · HD · contact PI
Dysregulated arginine metabolism in treated HIV infection$791,529
R56 · FY2014 · HL · contact PI
Incremental effect of smoking on HIV immune activation and cardiac health$788,433
R56 · FY2014 · HL · contact PI
Inflammation, Heart and Bone$477,871
R01 · FY2014 · NR · contact PI
Vitamin D, drug metabolism, and cardiovascular complications in pediatric HIV$323,555
R01 · FY2014 · HD · contact PI
Inflammation, Heart and Bone$474,649
R01 · FY2013 · NR · contact PI
Vitamin D, drug metabolism, and cardiovascular complications in pediatric HIV$317,134
R01 · FY2013 · HD · contact PI
Inflammation, Heart and Bone$513,955
R01 · FY2012 · NR · contact PI
Vitamin D, drug metabolism, and cardiovascular complications in pediatric HIV$334,267
R01 · FY2012 · HD · contact PI
Research Training in Pediatric Infectious Diseases$100,103
T32 · FY2012 · AI · contact PI
Inflammation, Heart and Bone$516,854
R01 · FY2011 · NR · contact PI
Vitamin D, drug metabolism, and cardiovascular complications in pediatric HIV$356,840
R01 · FY2011 · HD · contact PI
Research Training in Pediatric Infectious Diseases$123,070
T32 · FY2011 · AI · contact PI
Inflammation, Heart and Bone$533,182
R01 · FY2010 · NR · contact PI
Metabolic Consequences of Thymidine Sparing Regimens$171,460
R01 · FY2010 · AI · contact PI
Research Training in Pediatric Infectious Diseases$101,868
T32 · FY2010 · AI · contact PI
Role of Mitochondria in HIV Lipoatrophy$303,205
R01 · FY2009 · AI · contact PI
Metabolic Consequences of Thymidine Sparing Regimens$217,227
R01 · FY2009 · AI · contact PI
Research Training in Pediatric Infectious Diseases$6,586
T32 · FY2009 · AI · contact PI
Role of Mitochondria in HIV Lipoatrophy$477,550
R01 · FY2008 · AI · contact PI
Metabolic Consequences of Thymidine Sparing Regimens$212,681
R01 · FY2008 · AI · contact PI
Research Training in Pediatric Infectious Diseases$120,590
T32 · FY2008 · AI · contact PI
Role of Mitochondria in HIV Lipoatrophy$473,090
R01 · FY2007 · AI · contact PI
Uridine Supplementation for HIV lipoatrophy$262,356
R21 · FY2007 · AT · contact PI
Metabolic Consequences of Thymidine Sparing Regimens$212,299
R01 · FY2007 · AI · contact PI
Role of Mitochondria in HIV Lipoatrophy$473,504
R01 · FY2006 · AI · contact PI
Metabolic Consequences of Thymidine Sparing Regimens$227,764
R01 · FY2006 · AI · contact PI
Training Program in Pediatric Infectious Diseases$176,233
T32 · FY2006 · AI · contact PI
Uridine Supplementation for HIV lipoatrophy$145,547
R21 · FY2006 · AT · contact PI
Role of Mitochondria in HIV Lipoatrophy$419,364
R01 · FY2005 · AI
Training Program in Pediatric Infectious Diseases$182,525
T32 · FY2005 · AI
Uridine Supplementation for HIV lipoatrophy$149,050
R21 · FY2005 · AT
Role of Mitochondria in HIV Lipoatrophy$191,250
R21 · FY2004 · AI
Training Program in Pediatric Infectious Diseases$180,167
T32 · FY2004 · AI
Longitudinal assessment of mtDNA kinetics in pts on NRTI-containing HAART$8,318
M01 · FY2004 · RR